Patients with smoldering multiple myeloma (SMM), an asymptomatic form of myeloma, do not benefit from treatment with the anti-ICAM1 antibody BI-505, according to the results…
Myeloma
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Latest news
A Phase 1 trial will soon be assessing Actimab-M, an anti-CD33 antibody bound to a radioactive compound, in heavily treated multiple myeloma patients, the compound’s developer,…
People with chronic diseases value the Affordable Care Act (ACA), commonly known as Obamacare, more than Americans in general, a survey by PatientsLikeMe has found. They are also…
A new immunotherapy using natural killer cells showed promise in a small proof-of-concept Phase 1 trial of relapsed or refractory multiple myeloma patients who also…
Multiple myeloma patients older than 65 years benefit as much as younger patients from autologous stem cell transplant (ASCT), according to a recent retrospective study.
A combination treatment of four drugs including the chemotherapy agent Alkeran (melphalan) gives excellent short-term outcomes in multiple myeloma patients who undergo stem cell transplants,…
